Drug Type Interleukins |
Synonyms IL-22 Program(Synthekine), STK 038, STK038 |
Target |
Action agonists |
Mechanism IL-22 agonists(Interleukin-22 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Obesity | Preclinical | United States | 01 May 2026 | |
| Inflammation | Preclinical | United States | 27 Mar 2024 | |
| Metabolic Diseases | Preclinical | United States | 27 Mar 2024 |






